TB-500: Thymosin Beta-4 and Tissue Regeneration

EXOMA Scientific Team · Publicado el 5 de enero de 2026 · Actualizado el 24 de agosto de 2026

Analysis of the scientific literature on TB-500 and its role in cell migration and angiogenesis in in vitro and in vivo studies.

TB-500: Thymosin Beta-4 and tissue regeneration

TB-500 is one of the most requested peptides in the field of tissue-recovery research, almost always named alongside BPC-157. Behind that popularity is a molecule with a concrete biology: it is a synthetic fragment derived from the Thymosin Beta-4, a natural protein involved in the dynamics of the actin cytoskeleton. In this technical guide we break down its data sheet, its mechanism of action at the molecular level, how it compares with BPC-157 and what you should consider in laboratory handling —reconstitution, storage and purity verification— all under a strictly for scientific research.

If you are looking for the quick reference of hard data, you have it in the TB-500 compendium; here we expand on the reason for each figure.

Technical data

The TB-500 available for research corresponds to a peptide derived from Thymosin Beta-4. Its verified physicochemical parameters are:

The central datum for understanding its function is the sequence LKKTETQ. This heptapeptide—Leucine-Lysine-Lysine-Threonine-Glutamate-Threonine-Glutamine—is the canonical actin-binding motif of the beta-thymosin family and is directly responsible for the biological activity under study. The complete molecule is presented N-acetylated (Ac-), a modification at the amino terminus associated with greater stability against exopeptidases.

A clarification of nomenclature is warranted: native Thymosin Beta-4 is a 43-residue protein. The term "TB-500" is used broadly in the research market to refer both to the complete molecule and, in some contexts, to the active region. The material we characterize here corresponds to the 43-amino-acid peptide with its indicated sequence and mass.

How it sequesters G-actin: the LKKTETQ mechanism

To understand TB-500, one must understand actin. Actin is one of the most abundant proteins in the cell and exists in two forms in equilibrium: the G-actin, monomeric and globular, free in the cytoplasm; and the F-actin, filamentous, that results from the polymerization of those monomers. That dynamic equilibrium—assembling and disassembling filaments—is what allows a cell to change shape, migrate, and reorganize its internal structure.

Here is the reason LKKTETQ. The best-characterized function of Thymosin Beta-4 is that of sequester monomeric G-actin: it binds to the free monomers through its binding motif (residues 17-23) and keeps them in a non-polymerized reserve. By regulating how much G-actin is available, the molecule influences the rate of polymerization and depolymerization of the filaments.

In functional terms, acting on this balance has a direct consequence: it modulates the cell migration. A cell that needs to move —for example, in the tissue-reorganization processes studied in repair models— depends on rapidly recycling its actin cytoskeleton. That is why the research interest in TB-500 concentrates on contexts of cell motility and remodeling.

Angiogenesis and endothelial migration

In addition to its role on actin, in the literature Thymosin Beta-4 is associated with the promotion of angiogenesis, that is, the formation of new vessels from pre-existing vessels. The described mechanism works by favoring the proliferation and migration of endothelial cells (those that line the interior of the blood vessels).

The two properties fit together coherently: endothelial migration is, at its core, another manifestation of actin dynamics. An endothelial cell forming a new vascular sprout reorganizes its cytoskeleton in order to extend and move. Hence TB-500 is investigated as a tool to explore processes where cell motility and microvascular development converge, always in experimental models and for research.

TB-500 versus BPC-157: comparison of objective data

The most frequent question in research forums is how TB-500 and the ... differ BPC-157. They are very different molecules in size and origin, although both are studied in the field of tissue remodeling. The table summarizes the hard facts of each one:

The reading of the table is clear. BPC-157 is a molecule much smaller (about 3.5 times less mass) and of fully defined sequence in its 15 residues. Its mechanism, according to the preclinical literature, relies on vascular signaling pathways (VEGF/VEGFR2, eNOS/nitric oxide) and even on a described interaction with the dopaminergic system. TB-500, on the other hand, acts on the structural machinery of the cell —the actin cytoskeleton— through its LKKTETQ motif.

Neither of the two half-lives is well documented in the public sources reviewed, so any figure circulating in this regard must be taken as approximate. For the molecular detail of each one, consult the TB-500 compendium and the BPC-157 compendium.

Why they are studied together

The TB-500 + BPC-157 pairing is not incidental; it reflects that their mechanisms, as described above, operate on distinct and potentially complementary planes. BPC-157 provides a profile oriented toward vascular signaling (VEGF/VEGFR2, nitric oxide) and TB-500 provides the regulation of the actin cytoskeleton and cell migration. Both converge on the phenomenon of angiogenesis, but they reach it by different routes.

That logic of "a small signaling peptide + a structural protein fragment" is what motivates many research protocols to place them in the same experimental design. It is important to emphasize that this is a mechanistic complementarity hypothesis posited in the preclinical setting, not a claim of results. You can explore both molecules within the recovery category.

Applications in preclinical models

The legitimate use of TB-500 is as research reagent in experimental models. The lines of study derive directly from its mechanism, without the need to attribute to it results that are not characterized:

• Actin cytoskeleton dynamics: its ability to sequester G-actin makes it useful for investigating the G/F-actin balance in cell cultures.
• Cell migration: models that study motility and gap closure in cell monolayers.
• Experimental angiogenesis: endothelial proliferation and migration assays.
• Tissue remodeling: contexts where structural reorganization is investigated.

In all cases, the framework is for scientific research. This material is not intended for other uses, and any conclusion must be derived from one's own experimental data, not from expectations of efficacy.

Reconstitution math

TB-500 is distributed lyophilized (as a powder) and requires reconstitution with a suitable diluent —typically bacteriostatic water or sterile water- before handling it in the laboratory. Lyophilization is the freeze-drying process that removes water from the peptide to stabilize it during transport and storage.

The calculation principle is simple: the concentration resulting is equal to the mass of the peptide divided by the volume of diluent you add.

Concentration = mass of peptide ÷ volume of diluent

If you add more diluent, the concentration drops; if you add less, it rises. Since TB-500 is handled in quantities on the order of milligrams and laboratory draws in fractions of a milliliter, doing the arithmetic by hand invites errors. For this reason it is advisable to rely on dedicated tools:

• La reconstitution calculator to obtain the concentration and the volume to draw according to your objective.
• La vial calculator to plan how much a vial yields.
• El unit converter to convert between mg, mcg and mL without confusion.

Avoid reconstituting with a direct stream onto the lyophilized pellet; it is recommended to let the diluent run down the wall of the vial and to dissolve with gentle movements, without vigorous shaking, so as not to stress the molecule. The complete step-by-step is in the reconstitution guide for lyophilized peptides.

Storage: lyophilized vs. reconstituted

The physical state of the peptide completely changes its storage requirements:

The rule of thumb: reconstitute only what you are going to use within your working window and keep the rest lyophilized. Repeated exposure to room temperature, light and freeze-thaw cycles is what most deteriorates a peptide in solution.

Purity and COA

For research, purity is not a marketing detail: it is a reproducibility requirement. A peptide with impurities introduces variables that contaminate your results. The two elements you must verify are:

• HPLC (high-performance liquid chromatography): is the standard technique for quantifying peptide purity, separating the main compound from its impurities and reporting it as a percentage.
• Mass spectrometry: confirms that the molecular mass of the material corresponds to the expected value -in the case of TB-500, around 4963.44 Da— that is, that the synthesized molecule is indeed what it claims to be.

Both results are consolidated in the COA (Certificate of Analysis) of the lot. Reviewing the COA before designing an experiment is good practice: it confirms the identity (mass) and quality (HPLC purity) of the material you actually have in hand. You can consult the data sheet and availability on the page of TB-500.

Logistics in Mexico

The material is prepared and dispatched from Mexico, which reduces times versus importing:

• Preparation: maximum 1 business day.
• Shipping: 1 to 3 business days.
• Days of operation: Monday to Friday.

This means that an order placed at the beginning of the week is usually in transit quickly and arrives within the same week in much of the country.

FAQ

What exactly is TB-500?

It is a peptide derived from Thymosin Beta-4, of 43 amino acids and mass 4963.44 Da (CAS 77591-33-4). Its active region is the LKKTETQ motif, responsible for binding to actin. It is offered for scientific research.

What is its main mechanism?

It sequesters monomeric G-actin through its LKKTETQ motif (residues 17-23), regulating actin polymerization and cell migration, and is associated with the promotion of angiogenesis through endothelial proliferation.

How does it differ from BPC-157?

TB-500 is a large protein fragment (43 aa) that acts on the actin cytoskeleton; BPC-157 is a small pentadecapeptide (15 aa) that, according to the literature, acts via VEGF/VEGFR2 and the nitric-oxide pathway. Compare them in detail in the comparator.

How long does it last reconstituted?

Its half-life is not well documented in public sources. As for practical stability, the lyophilized powder lasts much longer than the solution; once reconstituted, keep it refrigerated and protected from light, and use it within a short window.

How do I calculate the concentration?

Divide the peptide mass by the diluent volume. To avoid errors, use the reconstitution calculator.

Can it be used together with BPC-157?

In the preclinical setting they are studied together for their complementary mechanisms (structural vs. vascular signaling). It is a research hypothesis, not a claim of results. Both are in the recovery category.

Content solely informational and for scientific research (RUO). The data presented come from physicochemical characterization and general mechanistic literature; they do not constitute efficacy claims or usage guidance. Always verify the batch COA before designing your experiments.

References

Material for research use only. The following primary sources support the scientific claims of this article:

1. Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal. 2012;4(9):733-738. PMID 22962027.

Products available at EXOMA

• TB-500